<DOC>
	<DOCNO>NCT02208882</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability effect Midazolam pharmacokinetics multiple oral dos BMS-986120 healthy subject .</brief_summary>
	<brief_title>Multiple Ascending Dose Study Evaluate Safety , Tolerability Pharmacokinetics BMS-986120 Healthy Subjects Effects Co-Administration Midazolam BMS-986120</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com 1 . Healthy male female subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination 2 . Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive . BMI=Weight ( kg ) / [ Height ( ) ] 2 3 . Women childbearing potential ( i.e. , postmenopausal surgically sterile ) men , age 18 75 , inclusive 1 . Concurrent , use within 2weeks study drug administration , market investigational , nonsteroidal antiinflammatory compound ( NSAIDS ) , aspirin antiplatelet agent , oral parenteral anticoagulant 2 . Subjects screen prior first dose follow abnormal laboratory value upon repeat test exclude : ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; upper limit normal ( ULN ) ii ) Total bilirubin &gt; ULN , thyroidstimulating hormone ( TSH ) &gt; 1.5 x ULN T4 within normal limit ( Subjects mild unconjugated hyperbilirubinemia due Gilbert 's syndrome exclude ) iii ) CK &gt; 3 x ULN ( unless exercise relate CKMB within normal limit ) iv ) Activated partial thromboplastin ( aPTT ) Prothrombin Time ( PT ) /International Normalized Ratio ( INR ) &gt; ULN v ) Blood urea nitrogen ( BUN ) creatinine ( Cr ) &gt; ULN 3 . Hemoglobin hematocrit platelet count &lt; low limit normal ( LLN ) 4 . Bleeding time exceed 8 minute predose Day 1 5 . Subjects micro macrohematuria and/or fecal occult blood detect screening , baseline document recent medical assessment , unless deem clinically significant Investigator Medical Monitor 6 . Any significant acute chronic medical illness 7 . Current recent ( within 3 month study drug administration ) gastrointestinal disease 8 . Any major surgery within 12 week study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>